Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPLASH trial of 177Lu-PNT2002 versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer
NL-OMON54469Phase 3Recruiting
- Sponsor
- POINT Biopharma
- Start
- Jun 2022
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of Lu-PNT2002 in prostate cancer (PCa) (3 arms), sponsored by POINT Biopharma. Primary endpoint: Radiographic progression-free survival. Started Jun 2022; status: recruiting.
02
Drugs
Lu-PNT2002
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON54469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54469.